Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscien...

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)

Wedbush analyst maintained a Buy rating on Xencor yesterday and set a price target of $26.00. In addition to Wedbush, Xencor also received a Buy fr...

Wedbush Remains a Buy on Xencor (XNCR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ardent Health Partners, Inc. (ARDT), Xencor (XNCR) and Tarsus Pha...

Analysts Conflicted on These Healthcare Names: Ardent Health Partners, Inc. (ARDT), Xencor (XNCR) and Tarsus Pharmaceuticals (TARS)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Xencor, with a price target of $17.00. Accor...

Bank of America Securities Reaffirms Their Hold Rating on Xencor (XNCR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine...

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine (NBIX)

Xencor ( ($XNCR) ) has provided an announcement. On April 23, 2026, Xencor, Inc. adopted an Executive Severance Policy covering certain senior exec...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XNCR	$11.63	+2.83%	525.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XNCR	$11.63	+2.8%	525.77K
3
4
5
6

XNCR

XNCR

Get Xencor Inc. Data in Excel

Get Xencor Inc. Data in Excel